Loma Linda, California 92354

  • Amyotrophic Lateral Sclerosis


This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS There is no study medication being offered in this trial. Edaravone is prescribed as part of regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure certain markers that could indicate why the drug may be working in a specific type of ALS.


Inclusion Criteria: 1. Either possible, probable, or definite ALS, predominantly lower motor neuron disease, predominantly upper motor neuron disease, or bulbar 2. With or without cognitive involvement 3. Willing to participate 4. On no experimental treatment 5. Ages 18 - 85 6. No prior exposure to Edaravone (Radicava) 7. On a stable dose of Riluzole for 30 days or off Riluzole 8. Male or female 9. Females of childbearing age must use contraception Exclusion Criteria: 1. Unstable medical illness 2. Abnormal liver function (>2x ULN) 3. Unlikely to survive for 26 weeks



Primary Contact:

Principal Investigator
Jeffrey Rosenfeld, PhD, MD
Loma Linda University

Imran Qasim
Phone: (909) 558-2037 ext. 25388
Email: sqasim@llu.edu

Backup Contact:


Location Contact:

Loma Linda, California 92354
United States

Imran Qasim
Phone: 909-558-2037
Email: sqasim@llu.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 17, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.